Citadel Advisors
SAGE

Citadel Advisors’s Sage Therapeutics SAGE Stock Holding History

Citadel Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,200
Closed -$212K – 13926
2025
Q2 		$212K Sell
23,200
-1,800
-7% -$13.2K ﹤0.01% 10558
2025
Q1 		$199K Sell
25,000
-96,500
-79% -$707K ﹤0.01% 10454
2024
Q4 		$660K Buy
121,500
+3,400
+3% +$20.8K ﹤0.01% 7950
2024
Q3 		$853K Buy
118,100
+16,400
+16% +$150K ﹤0.01% 7183
2024
Q2 		$1.1M Buy
101,700
+88,600
+676% +$1.14M ﹤0.01% 6386
2024
Q1 		$245K Sell
13,100
-57,800
-82% -$1.33M ﹤0.01% 9905
2023
Q4 		$1.54M Sell
70,900
-41,900
-37% -$830K ﹤0.01% 5842
2023
Q3 		$2.32M Buy
112,800
+71,800
+175% +$2.07M ﹤0.01% 4950
2023
Q2 		$1.93M Buy
41,000
+15,100
+58% +$751K ﹤0.01% 5209
2023
Q1 		$1.09M Sell
25,900
-49,100
-65% -$2.11M ﹤0.01% 6585
2022
Q4 		$2.86M Sell
75,000
-500
-0.7% -$19.1K ﹤0.01% 4832
2022
Q3 		$2.96M Buy
75,500
+22,900
+44% +$885K ﹤0.01% 4835
2022
Q2 		$1.7M Sell
52,600
-29,800
-36% -$999K ﹤0.01% 5877
2022
Q1 		$2.73M Sell
82,400
-9,000
-10% -$338K ﹤0.01% 5402
2021
Q4 		$3.89M Sell
91,400
-35,200
-28% -$1.47M ﹤0.01% 4810
2021
Q3 		$5.61M Sell
126,600
-11,600
-8% -$532K ﹤0.01% 4091
2021
Q2 		$7.85M Buy
138,200
+36,900
+36% +$2.61M ﹤0.01% 3536
2021
Q1 		$7.58M Buy
101,300
+8,000
+9% +$656K ﹤0.01% 3431
2020
Q4 		$8.07M Sell
93,300
-39,900
-30% -$2.94M ﹤0.01% 2928
2020
Q3 		$8.14M Buy
133,200
+38,300
+40% +$1.94M ﹤0.01% 2538
2020
Q2 		$3.95M Buy
94,900
+6,300
+7% +$229K ﹤0.01% 3420
2020
Q1 		$2.54M Sell
88,600
-221,000
-71% -$12.8M ﹤0.01% 3750
2019
Q4 		$22.4M Buy
309,600
+192,100
+163% +$23.6M 0.01% 1374
2019
Q3 		$16.5M Buy
117,500
+21,300
+22% +$3.56M 0.01% 1670
2019
Q2 		$17.6M Buy
96,200
+44,700
+87% +$7.63M 0.01% 1546
2019
Q1 		$8.19M Sell
51,500
-86,800
-63% -$12.6M ﹤0.01% 2310
2018
Q4 		$13.2M Buy
138,300
+86,500
+167% +$9.9M 0.01% 1600
2018
Q3 		$7.32M Buy
51,800
+11,400
+28% +$1.76M ﹤0.01% 2523
2018
Q2 		$6.32M Buy
40,400
+13,000
+47% +$2.04M ﹤0.01% 2460
2018
Q1 		$4.41M Sell
27,400
-18,400
-40% -$3.12M ﹤0.01% 2602
2017
Q4 		$7.54M Buy
45,800
+12,700
+38% +$1.23M ﹤0.01% 2010
2017
Q3 		$2.06M Sell
33,100
-3,000
-8% -$236K ﹤0.01% 3373
2017
Q2 		$2.88M Buy
36,100
+7,900
+28% +$571K ﹤0.01% 2708
2017
Q1 		$2M Buy
28,200
+16,100
+133% +$943K ﹤0.01% 3079
2016
Q4 		$618K Sell
12,100
-2,300
-16% -$108K ﹤0.01% 4570
2016
Q3 		$663K Buy
14,400
+2,900
+25% +$118K ﹤0.01% 4417
2016
Q2 		$346K Buy
+11,500
New +$383K ﹤0.01% 5012
2016
Q1 		– Sell
-8,600
Closed -$501K – 7797
2015
Q4 		$501K Buy
8,600
+500
+6% +$24.8K ﹤0.01% 4469
2015
Q3 		$343K Buy
8,100
+6,000
+286% +$370K ﹤0.01% 5360
2015
Q2 		$153K Buy
+2,100
New +$135K ﹤0.01% 6638

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's SAGE Position: Q3 2025 in Review

Citadel Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 178,337 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in SAGE in Q3 2014 and held it in 43 quarters. The position peaked at $87.1M in Q3 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Citadel Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 178,337 Sage Therapeutics shares in Q3 2025, an estimated $1.63M.
  • Citadel Advisors first reported a position in Sage Therapeutics in Q3 2014 and held it in 43 quarters.
  • Citadel Advisors's Sage Therapeutics position peaked at $87.1M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.